A potentially life-changing heart condition, dilated cardiomyopathy, can be caused by the cumulative influence of hundreds or ...

Acoramidis (Attruby) gained FDA approval for treating wild-type or variant transthyretin (TTR) amyloidosis cardiomyopathy ...

On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...

Research indicates that dilated cardiomyopathy can be caused by the cumulative influence of potentially thousands of genes, not just one single genetic variant.

Ischemic cardiomyopathy changes how the heart pumps blood because of muscle damage. Learn about the role of medication in ...

The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse ...

But were they any more effective than other drugs that use older, less sci-fi technologies? Intellia tried to allay some of ...

Vutrisiran, a transthyretin-directed small interfering RNA therapeutic, is currently approved under the brand name Amvuttra ® for the treatment of polyneuropathy manifestations of hereditary ...

Favorable short- and long-term outcomes are seen in patients with hypertrophic cardiomyopathy who receive septal reduction therapy.

The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...

Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.

But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...